ATE476524T1 - RISK ASSESSMENT OF NEGATIVE DRUG REACTIONS - Google Patents

RISK ASSESSMENT OF NEGATIVE DRUG REACTIONS

Info

Publication number
ATE476524T1
ATE476524T1 AT04776718T AT04776718T ATE476524T1 AT E476524 T1 ATE476524 T1 AT E476524T1 AT 04776718 T AT04776718 T AT 04776718T AT 04776718 T AT04776718 T AT 04776718T AT E476524 T1 ATE476524 T1 AT E476524T1
Authority
AT
Austria
Prior art keywords
hla
allele
sjs
induced
markers
Prior art date
Application number
AT04776718T
Other languages
German (de)
Inventor
Yuan-Tsong Chen
Shuen-Iu Hung
Wen-Hung Chung
Jer-Yuarn Wu
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34552314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476524(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica filed Critical Academia Sinica
Application granted granted Critical
Publication of ATE476524T1 publication Critical patent/ATE476524T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.
AT04776718T 2003-11-10 2004-06-18 RISK ASSESSMENT OF NEGATIVE DRUG REACTIONS ATE476524T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/705,245 US7470513B2 (en) 2003-11-10 2003-11-10 Risk assessment for adverse drug reactions
PCT/US2004/019435 WO2005047544A1 (en) 2003-11-10 2004-06-18 Risk assessment for adverse drug reactions

Publications (1)

Publication Number Publication Date
ATE476524T1 true ATE476524T1 (en) 2010-08-15

Family

ID=34552314

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776718T ATE476524T1 (en) 2003-11-10 2004-06-18 RISK ASSESSMENT OF NEGATIVE DRUG REACTIONS

Country Status (16)

Country Link
US (5) US7470513B2 (en)
EP (1) EP1697539B1 (en)
CN (1) CN1902328B (en)
AT (1) ATE476524T1 (en)
AU (1) AU2004289951B2 (en)
BR (1) BRPI0416355A (en)
CA (1) CA2544369C (en)
CY (1) CY1110760T1 (en)
DE (1) DE602004028508D1 (en)
DK (1) DK1697539T3 (en)
ES (1) ES2347150T3 (en)
PL (1) PL1697539T3 (en)
PT (1) PT1697539E (en)
SI (1) SI1697539T1 (en)
TW (1) TWI287580B (en)
WO (1) WO2005047544A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US20060166224A1 (en) * 2005-01-24 2006-07-27 Norviel Vernon A Associations using genotypes and phenotypes
US7452689B2 (en) * 2005-05-20 2008-11-18 Mayo Foundation For Medical Education And Research Method for rapid determination of thiopurine methyltransferase activity
PT2016198E (en) * 2006-05-11 2013-07-29 Academia Sinica Method for predicting a risk of adverse drug reactions by determination of hla-b 1502
AU2009298669B2 (en) * 2008-10-01 2016-04-07 The Arizona Board Of Regents, On Behalf Of The University Of Arizona Glucuronidated acetaminophen as a marker of hepatic disorders
CN102108382A (en) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 Genetic testing for risk of causing serious adverse reactions of skin of carbamazepine
JP5996524B2 (en) 2010-04-12 2016-09-21 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Method for identifying HLA complexes associated with adverse drug reactions
WO2012174723A1 (en) * 2011-06-23 2012-12-27 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung Risk assessment for phenytoin-induced adverse drug reactions
CN105039579B (en) * 2011-06-23 2018-10-02 长庚医疗财团法人基隆长庚纪念医院 Cause the method for drug anaphylaxis with HLA allele assessment antiepileptic phenytoinum naticum
CN102296109A (en) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 SYBR Green I detection method for HLA-B*1502 gene, special primer thereof and kit thereof
TW201307846A (en) * 2011-08-02 2013-02-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung Method for assessing adverse drug reaction (ADR) or allergic reaction risk incurred by antiepileptic drug
US10370409B2 (en) 2011-10-25 2019-08-06 The Scripps Research Institute Synthesis of libraries of peptide tertiary amides
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102925567B (en) * 2012-10-23 2013-12-11 山东省皮肤病性病防治研究所 Use of HLA-B*1301 alleles
KR102208505B1 (en) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 Methods for high throughput receptor:ligand identification
JP2015107095A (en) * 2013-03-14 2015-06-11 凸版印刷株式会社 Evaluation method of risk of onset of severe drug eruption accompanied by ophthalmic complications
CN104818316B (en) * 2013-11-28 2018-09-21 复旦大学 Human leukocyte antigen gene detecting kit for dermal drug adverse reaction caused by screening salicylazosulfapyridine
CN103646185A (en) * 2013-12-25 2014-03-19 顾德国 Adverse drug reaction (ADR) report quality evaluation system and ADR report quality evaluation method
CN104017898B (en) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 The allelic primer of rapid detection HLA-B*5801, test kit and method
KR101591603B1 (en) * 2014-10-16 2016-02-04 연세대학교 산학협력단 Method of providing the information for predicting adverse drug reaction
CN104450914A (en) * 2014-12-10 2015-03-25 苏州旷远生物分子技术有限公司 Primers, probe, fluorescent PCR kit and method for detecting human HLA-B*1502 gene
US9927443B2 (en) * 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
US9932638B2 (en) 2015-06-29 2018-04-03 Millennium Health, LLC Single nucleotide polymorphism in HLA-B*15:02 and use thereof
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP6395061B2 (en) * 2016-06-21 2018-09-26 チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン How to assess the risk of side effects of drugs induced by phenytoin
AU2017379900A1 (en) 2016-12-22 2019-06-13 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
US11289178B2 (en) 2017-04-21 2022-03-29 International Business Machines Corporation Identifying chemical substructures associated with adverse drug reactions
SG11202003391XA (en) * 2017-10-27 2020-05-28 Chang Gung Memorial Hospital Linkou Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN108342457B (en) * 2018-04-01 2021-12-07 广东辉锦创兴生物医学科技有限公司 HLA-B5801 allele detection kit and application thereof
CN108866007A (en) * 2018-04-26 2018-11-23 厦门敖依生物科技有限公司 A kind of monoclonal antibody and the preparation method and application thereof detecting HLA-B*5801
WO2020182189A1 (en) * 2019-03-12 2020-09-17 Chang Gung Memorial Hospital, Linkou Methods for detecting or reducing the incidence of adverse drug reactions
CA3137521A1 (en) * 2019-05-06 2020-11-12 Chang Gung Memorial Hospital, Linkou Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
TWI804620B (en) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 Methods and kits for detecting dmard-induced severe cutaneous adverse drug reactions and usesof the kits
US11763946B2 (en) * 2020-02-27 2023-09-19 Optum, Inc. Graph-based predictive inference
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2023541366A (en) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド MHC class II T cell modulating multimeric polypeptides and methods of use thereof to treat type 1 diabetes mellitus (T1D)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550039A (en) * 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Also Published As

Publication number Publication date
SI1697539T1 (en) 2010-11-30
US20130330724A1 (en) 2013-12-12
CN1902328A (en) 2007-01-24
AU2004289951B2 (en) 2009-10-22
EP1697539B1 (en) 2010-08-04
CA2544369C (en) 2014-08-05
US7470513B2 (en) 2008-12-30
ES2347150T3 (en) 2010-10-26
TW200525038A (en) 2005-08-01
CA2544369A1 (en) 2005-05-26
CN1902328B (en) 2010-10-20
AU2004289951A1 (en) 2005-05-26
US20050100926A1 (en) 2005-05-12
US20120077192A1 (en) 2012-03-29
US20090053727A1 (en) 2009-02-26
US7964351B2 (en) 2011-06-21
DK1697539T3 (en) 2010-11-22
DE602004028508D1 (en) 2010-09-16
US9562268B2 (en) 2017-02-07
EP1697539A1 (en) 2006-09-06
US20080227109A1 (en) 2008-09-18
PL1697539T3 (en) 2010-12-31
US8012686B2 (en) 2011-09-06
PT1697539E (en) 2010-10-04
WO2005047544A1 (en) 2005-05-26
BRPI0416355A (en) 2007-03-13
CY1110760T1 (en) 2015-06-10
TWI287580B (en) 2007-10-01

Similar Documents

Publication Publication Date Title
ATE476524T1 (en) RISK ASSESSMENT OF NEGATIVE DRUG REACTIONS
Rose et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly
Cavalli et al. MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo
Vijai et al. A genome-wide association study of marginal zone lymphoma shows association to the HLA region
MY150648A (en) Hla alleles associated with adverse drug reactions and methods for detecting such
BR112014001258B1 (en) DNA TYPING METHOD, AND, STARTER SETS FOR DNA TYPING
Reynolds et al. HLA–DRB1–associated rheumatoid arthritis risk at multiple levels in African Americans: hierarchical classification systems, amino acid positions, and residues
Kumar et al. Population structure, genetic variation and management of Marwari goats
Kerber et al. Gene expression profiles associated with aging and mortality in humans
Martínez et al. Role of the MHC2TA gene in autoimmune diseases
Yet et al. Genetic and environmental impacts on DNA methylation levels in twins
Nikolskiy et al. Using whole-genome sequences of the LG/J and SM/J inbred mouse strains to prioritize quantitative trait genes and nucleotides
Michot et al. A missense mutation in PFAS (phosphoribosylformylglycinamidine synthase) is likely causal for embryonic lethality associated with the MH1 haplotype in Montbéliarde dairy cattle
Gineau et al. Balancing immunity and tolerance: genetic footprint of natural selection in the transcriptional regulatory region of HLA-G
Lyons et al. Evidence for positive selection of taurine genes within a QTL region on chromosome X associated with testicular size in Australian Brahman cattle
MX2022009119A (en) AN EPIGENETIC CLOCK FOR <i>GALLIFORMES.
Pajnič Identification of a Slovenian prewar elite couple killed in the Second World War
JP2012187082A (en) Method for assessing drug eruption risk of antiepileptic drug based on single nucleotide polymorphism in 21.33 region of short arm of chromosome 6
Zajacova et al. Differences in promoter DNA methylation and mRNA expression of individual alleles of the HLA class II DQA1 gene
Sulovari et al. Atlas of human diseases influenced by genetic variants with extreme allele frequency differences
Nikamo et al. Cost‐effective HLA‐Cw06: 02 typing in a Caucasian population
Correa et al. HLA‐DR and DQB1 gene polymorphism in the North‐western Colombian population
Xiao et al. Association of HLA-DQA1 and DQB1 alleles with alolpecia areata in Chinese Hans
Velickovic et al. HLA‐DRB1 and HLA‐DQB1 polymorphisms in Pacific Islands populations
Li et al. Is a polymorphism in 10q25 associated with non-syndromic cleft lip with or without cleft palate? A meta-analysis based on limited evidence

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1697539

Country of ref document: EP